Supplier profile
Novartis Farmaceutica
Every public-sector award we hold for this supplier, across Spain and Mexico, from 23 Jan 2013 to 10 Oct 2024.
Awards won
456
all time
Attributed value
€4.1m + MXN 11.0bn
3 shared, unvalued
Buyers
7
public bodies
Active
2013–2024
first to latest award
Awards by year
Who they win from
| Buyer | Awards | Value |
|---|---|---|
| Servicio Madrileño de la Salud, Hospital Universitario Ramón y Cajal | 4 | €3.5m |
| Comunidad de Madrid; Consejería de Sanidad; Hospital General Universitario Gregorio Marañón | 1 | €147k |
| Consorci de Salut i d'Atenció Social de Catalunya | 1 | not attributable |
| Hospital Universitario Central de Asturias | 1 | not attributable |
| Inspección General de Sanidad de la Defensa | 1 | €212k |
| Servicio Extremeño de Salud; Gerencia del Área de Salud de Badajoz | 1 | €332k |
| Servicio Murciano de Salud | 1 | not attributable |
What they win
Awards
Showing 101–125 of 456 awards we hold
- Licitación Publica Consolidada de Medicamentos La-012M7B998-E165-2021 ↗£1.0m
- Compra Consolidada de Medicamentos y Material de Curación Primer Bloque 2024 ↗£82k
- Adjudicación Directa Intern. Consolidada No. Aa-051Gyn007-E30-2019, Medicamentos ↗£371.3m
- Compra Consolidada Medicamentos 2022 Aa-012M7B998-E197-2021 Int Abierta Patente ↗£3.6m
- Consolidada de 117 Claves de Medicamentos Patente Y/O Fuente Unica ↗£10.3m
- Compra Consolidada Medicamentos 2022 Aa-012M7B998-E198-2021 Internacional Bct ↗£984k
- Adquisicion Medicamentos Consolidada Aa-12-512-012000991-T-176-2023 ↗£193k
- Adquisicion Consolidada de Medicamentos y Bienes Terapeuticos (Fase Ll) ↗£811k
- Imatinib 100 Mg ↗£860k
- 13-0220A/2022 Req 256 Sana091 Medicinas y Productos Farmaceuticos ↗£36k
- Adquisición Consolidada de 135 Claves de Medicamentos y Bienes Terapéuticos 2022 Patente (Patente Y/O Fuente Única) ↗£7k
- Ribociclib. 254 Mg ↗£481k
- Consolidada de Medicamentos y Bienes Terapéuticos Fase 2 (Bct) ↗£12.0m
- Adquisicion Consolidada de 763 Claves de Medicamentos Para el Ejercicio 2024 ↗£3.3m
- Adquisición de Medicamentos y Material de Curacion de Consolidada Licitacion, Para Farmacia Hospitalaria y Farmacia Gratuidad 2023-2024 ↗£333k
- Adquisición Consolidada de 135 Claves de Medicamentos y Bienes Terapéuticos 2022 Patente (Patente Y/O Fuente Única) ↗£40.0m
- Basiliximab. Solucion Inyectable ↗£247k
- Adquisición de Claves de Medicamentos de Patente (11 Claves) y Fuente Única (7 Claves) ↗£640k
- Consolidada Para la Adq. de Medicamentos y Bienes T. ↗£2.0m
- Ruxolitinib 5 Mg. ↗£673k
- Medicamentos y Productos Farmaceuticos ↗£32k
- Insabi -Medicamentos y Bienes Terapéuticos E196-E197 y E198 ↗£19.8m
- Medicinas y Productos Farmaceuticos ↗£927k
- 010.000.6093.00 Ruxolitinib Tableta Cada Tableta Contiene: Fosfato de Ruxolitinib Equivalente a 5 Mg de Ruxolitinib Envase Con 60 Tabletas. ↗£141k
- Basiliximab 20 Mg ↗£420k
Possibly the same organisation
These entries differ from this one only by legal form or a bracketed qualifier, so they may be the same organisation — or a different registered company of the same name. They are kept apart on purpose: the figures on each page are per legal entity and are never combined.
Bidding against them?
Get new tenders in their space in a daily digest, scored against your own capability — plus the full notice behind each of these awards, with the documents and contacts it published.
Start 7-day free trialHow this profile is built
Awards are collected from official public procurement notices and deduplicated so one procurement counts once. Supplier names are grouped across their published spellings: case and punctuation are ignored, and “Ltd” is treated as optional because buyers routinely leave it off. Everything else that marks a different organisation is kept — an LLP, a plc, a CIC and a Teoranta are separate businesses from a Ltd of the same name, as are a parent and a named subsidiary, and none of them are merged here. Where another entry differs from this one only by legal form or a bracketed qualifier it is listed above as possibly the same organisation — a hint for the reader, never a merge: figures are per legal entity and never combined. Value is attributed only where the notice is explicit: the supplier's own itemised amount, or the whole value where they were the sole named supplier. Awards naming several suppliers without a published split are counted and marked shared, never valued, and a framework ceiling is never treated as money any one appointed supplier won. Sterling and euro are never added together. The linked source notice is authoritative.
Company pages are for organisations. If this page profiles you as an individual — a sole trader or an individual contractor — you can ask for it to be withheld: see how.